The average P/S ratio for ITCI's competitors is 18.25, providing a benchmark for relative valuation. Intra-Cellular Therapies Inc Corp (ITCI) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 50.81%, this premium appears sustainable.